ADC Therapeutics

Yahoo Finance • 3 days ago

Strategists are bullish on healthcare in 2026: 3 top stock picks

Catalyst Funds chief investment officer and senior portfolio manager David Miller and Marketgauge.com chief strategist Michele Schneider join Morning Brief host Julie Hyman to share some of their top stock picks in the healthcare (XLV) sec... Full story

Yahoo Finance • 23 days ago

ADC Therapeutics To Provide Update On LOTIS-7 Clinical Trial

(RTTNews) - ADC Therapeutics. (ADCT) is scheduled to host a conference call today at 8:00 a.m. EST to provide an update on its LOTIS-7 trial. LOTIS-7 is a Phase 1b open-label clinical trial evaluating the safety and efficacy of the compan... Full story

Yahoo Finance • last month

ADC Therapeutics Non-GAAP EPS of -$0.19, revenue of $15.8M misses by $0.99M

* ADC Therapeutics press release [https://seekingalpha.com/pr/20300217-adc-therapeutics-reports-third-quarter-2025-financial-results-and-provides-operational-update] (ADCT [https://seekingalpha.com/symbol/ADCT]): Q3 Non-GAAP EPS of -$0.1... Full story

Yahoo Finance • 2 months ago

Breast Cancer Antibody Drug Conjugates Market Research 2025-2030: $7 Billion Market Led by Daiichi Sankyo and AstraZeneca, with Rising Competition from Roche, Pfizer/Seagen, ADC Therapeutics

Company Logo The main market opportunities for breast cancer antibody drug conjugates (ADCs) lie in addressing unmet needs in HER2-positive and HER2-low tumors, leveraging precision targeting and reducing systemic toxicity. Key areas incl... Full story

Yahoo Finance • 3 months ago

ADC Therapeutics S.A. (ADCT) Eyes Billion Dollar Opportunity with ZYNLATA Indication Expansion

ADC Therapeutics S.A. (NYSE:ADCT) is one of the best performing penny stocks to buy now. On September 3 at the Cantor Global Healthcare Conference 2025, the company reiterated that it remains focused on expanding ZYNLATA’s use in DLBCL, ai... Full story

Yahoo Finance • 6 months ago

ADC Therapeutics files to sell 27.73M common shares by selling shareholders

* ADC Therapeutics (NYSE:ADCT [https://seekingalpha.com/symbol/ADCT]) filed a prospectus to sale 27.73 million shares of common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selling sharehol... Full story

Yahoo Finance • 6 months ago

ADC reports data from lymphoma trial, streamlines operations

[Business agreement] mediaphotos/iStock via Getty Images ADC Therapeutics (NYSE:ADCT [https://seekingalpha.com/symbol/ADCT]), on Thursday, reported results from an early stage trial testing its antibody drug conjugate, Zynlonta, in combin... Full story

Yahoo Finance • 2 years ago

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibiti... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics berichtet über die Finanzergebnisse des dritten Quartals 2023 und gibt aktuelle Geschäftsinformationen bekannt

Der Umsatz von ZYNLONTA®1 im 3. Quartal 2023 in Höhe von 14,3 Mio. USD spiegelt die Unterbrechung nach der Umstrukturierung der kommerziellen Organisation, den verstärkten Wettbewerb und die höheren Brutto-Netto-Abzüge wider Die Betriebsk... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics erhält Mitteilung der NYSE über Nichteinhaltung der Standards für die fortgesetzte Börsennotierung

LAUSANNE, Schweiz, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass das Unternehmen am 10. Oktober 2023 von der New York Stock Exchange (NYSE) die Mitteilung erhalten hat, dass es die Krit... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with t... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

3Q 2023 ZYNLONTA®1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions Operating expenses decreased 23%2 year-over-yeardue to portfolio... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tu... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics nimmt an der Jefferies London Healthcare Conference teil

LAUSANNE, Schweiz, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass Ameet Mallik, Chief Executive Officer, auf der Jefferies London Healthcare Conference am Dienstag, den 14. November um 10:00 Uh... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics gibt die Annahme von Abstracts zur Präsentation auf der 65. ASH-Jahrestagung bekannt

Präsentationen zur Hervorhebung des klinischen Nutzens von ZYNLONTA® (Loncastuximab-Tesirin-Lpyl) als Einzelwirkstoff und in Kombination Mündliche Präsentation der ersten Ergebnisse der von einem Prüfarzt initiierten Phase-II-Studie zur B... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include initial results of investigator-initiated Phase 2 study evaluating ZYNLONTA in combin... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics veranstaltet am 7. November 2023 eine Telefonkonferenz zu den Finanzergebnissen des dritten Quartals 2023

LAUSANNE, Schweiz, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass es am Dienstag, den 7. November 2023, um 8:30 Uhr EDT eine Telefonkonferenz und einen Live-Webcast abhalten wird, um über die F... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023

LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m. ET to report financial results for t... Full story

Yahoo Finance • 2 years ago

Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO

LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today anno... Full story

Yahoo Finance • 2 years ago

ADC Therapeutics nimmt im September an Anlegerkonferenzen teil

LAUSANNE, Schweiz, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass Ameet Mallik, Chief Executive Officer, im September an zwei Anlegerkonferenzen teilnehmen wird. Die Einzelheiten zu de... Full story